Titan Pharma (TTNP) Reports Q2 Loss of $0.11, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results
November 14, 2018 4:01 PM ESTSOUTH SAN FRANCISCO, Calif., Nov. 14, 2018 /PRNewswire/ --Â Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing and commercializing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura long-term, continuous drug delivery technology, today reported financial results for the third quarter ended September 30, 2018, and provided an update on its business.
... More